This report summarizes equity research changes for AIR Global, MBX Biosciences, and Phreesia. It provides revised ratings, price targets, and estimate adjustments for these small-cap entities.
Key Takeaways
- 1.AIR Global initiated at Overweight with a $9 price target due to resilient shisha molasses volumes and strong cash conversion.
- 2.MBX Biosciences remains Overweight despite 52-week PTH data coming in below investor expectations, with focus shifted to obesity data in 4Q.
- 3.Phreesia rating maintained at Equal Weight due to limited visibility following the AccessOne integration and evolving pharma ad market.
Table of Contents
- Summary of Changes
- Publications Summary
- Explanation of Summary of Changes table
- Analyst(s) Certification(s)
- Important Disclosures
- Availability of Disclosures
- Risk Disclosure(s)
- Guide to the Barclays Fundamental Equity Research Rating System
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Pallav MittalMorayo AdesinaLaurence WhyattWarren AckermanEliana MerleGlen SantangeloPeter WarendorfJenna Davidner
Securities
AIIR.OQMBXPHR
Themes
Small-cap equity valuationsBiotechnology clinical data response
Regions
North AmericaUnited States